B-Raf is required for ERK activation and tumor progression in a mouse model of pancreatic Β-cell carcinogenesis

Oncogene

Volumn 27, Issue 35, 2008, Pages 4779-4787

  Sobczak, I ^a   Galabova Kovacs, G ^a   Sadzak, I ^a   Kren, A ^b   Christofori, G ^b   Baccarini, M ^a  

^a UNIVERSITY OF VIENNA   (Austria)

^b UNIVERSITY OF BASEL   (Switzerland)

Author keywords

Angiogenesis; ERK pathway; Raf kinases; Tumor progression

Indexed keywords

B RAF KINASE; MITOGEN ACTIVATED PROTEIN KINASE;

ANIMAL CELL; ANIMAL CELL CULTURE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD VESSEL; CANCER CELL CULTURE; CANCER GROWTH; CANCER MODEL; CARCINOGENESIS; CELL PROLIFERATION; CONTROLLED STUDY; ENZYME ACTIVATION; GENE INACTIVATION; IN VITRO STUDY; IN VIVO STUDY; MALIGNANT TRANSFORMATION; MOUSE; NONHUMAN; PANCREAS ADENOMA; PANCREAS ISLET BETA CELL; PANCREAS ISLET CELL CARCINOMA; PRIORITY JOURNAL; PROTEIN FUNCTION; TUMOR SUPPRESSOR GENE;

ANIMALS; BASE SEQUENCE; CELL TRANSFORMATION, NEOPLASTIC; DISEASE MODELS, ANIMAL; DISEASE PROGRESSION; DNA PRIMERS; ENZYME ACTIVATION; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; IMMUNOHISTOCHEMISTRY; ISLETS OF LANGERHANS; MICE; MICE, KNOCKOUT; PANCREATIC NEOPLASMS; PROTO-ONCOGENE PROTEINS B-RAF; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; TRANSFORMING GROWTH FACTOR BETA; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 49749110755     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/onc.2008.128     Document Type: Article

References (45)

1. Abdulkadir SA, Qu Z, Garabedian E, Song S-K, Peters TJ, Svaren J et al. (2001). Impaired prostate tumorigenesis in Egr1-deficient mice. Nat Med 7: 101-107.
2. Ahlgren U, Jonsson J, Jonsson L, Simu K, Edlund H. (1998). beta-cell-specific inactivation of the mouse Ipf1/Pdx1 gene results in loss of the beta-cell phenotype and maturity onset diabetes. Genes Dev 12: 1763-1768.
3. Baron V, Adamson ED, Calogero A, Ragona G, Mercola D. (2005). The transcription factor Egr1 is a direct regulator of multiple tumor suppressors including TGF[beta]1, PTEN, p53, and fibronectin. Cancer Gene Ther 13: 115.
4. Bergers G, Brekken R, McMahon G, Vu TH, Itoh T, Tamaki K et al. (2000). Matrix metalloproteinase-9 triggers the angiogenic switch during carcinogenesis. Nat Cell Biol 2: 737-744.
5. Bergers G, Javaherian K, Lo KM, Folkman J, Hanahan D. (1999). Effects of angiogenesis inhibitors on multistage carcinogenesis in mice. Science 284: 808-812.
6. Bild AH, Yao G, Chang JT, Wang Q, Potti A, Chasse D et al. (2006). Oncogenic pathway signatures in human cancers as a guide to targeted therapies. Nature 439: 353-357.
7. Casanovas O, Hicklin DJ, Bergers G, Hanahan D. (2005). Drug resistance by evasion of antiangiogenic targeting of VEGF signaling in late-stage pancreatic islet tumors. Cancer Cell 8: 299-309.
8. Cavallaro U, Christofori G. (2001). Cell adhesion in tumor invasion and metastasis: loss of the glue is not enough. Biochim Biophys Acta 1552: 39-45.
9. Chen AP, Ohno M, Giese KP, Kuhn R, Chen RL, Silva AJ. (2006). Forebrain-specific knockout of B-raf kinase leads to deficits in hippocampal long-term potentiation, learning, and memory. J Neurosci Res 83: 28-38.
10. Compagni A, Wilgenbus P, Impagnatiello MA, Cotten M, Christofori G. (2000). Fibroblast growth factors are required for efficient tumor angiogenesis. Cancer Res 60: 7163-7169.
11. De Benedetti A, Graff JR. (2004). eIF-4E expression and its role in malignancies and metastases. Oncogene 23: 3189-3199.
12. Downward J. (2006). Cancer biology: signatures guide drug choice. Nature 439: 274-275.
13. Dumaz N, Hayward R, Martin J, Ogilvie L, Hedley D, Curtin JA et al. (2006). In melanoma, RAS mutations are accompanied by switching signaling from BRAF to CRAF and disrupted cyclic AMP signaling. Cancer Res 66: 9483-9491.
14. Efrat S, Linde S, Kofod H, Spector D, Delannoy M, Grant S et al. (1988). Beta-cell lines derived from transgenic mice expressing a hybrid insulin gene-oncogene. Proc Natl Acad Sci USA 85: 9037-9041.
15. Eid MA, Kumar MV, Iczkowski KA, Bostwick DG, Tindall DJ. (1998). Expression of early growth response genes in human prostate cancer. Cancer Res 58: 2461-2468.
16. Emuss V, Garnett M, Mason C, Marais R. (2005). Mutations of C-RAF are rare in human cancer because C-RAF has a low basal kinase activity compared with B-RAF. Cancer Res 65: 9719-9726.
17. Ferrara N, Gerber HP, LeCouter J. (2003). The biology of VEGF and its receptors. Nat Med 9: 669-676.
18. Galabova-Kovacs G, Kolbus A, Matzen D, Meissl K, Piazzolla D, Rubiolo C et al. (2006a). ERK and beyond: insights from B-Raf and Raf-1 conditional knockouts. Cell Cycle 5: 1514-1518.
19. Galabova-Kovacs G, Matzen D, Piazzolla D, Meissl K, Plyushch T, Chen AP et al. (2006b). Essential role of B-Raf in ERK activation during extraembryonic development. Proc Natl Acad Sci USA 103: 1325-1330.
20. Garnett MJ, Marais R. (2004). Guilty as charged: B-RAF is a human oncogene. Cancer Cell 6: 313-319.
21. Gavert N, Conacci-Sorrell M, Gast D, Schneider A, Altevogt P, Brabletz T et al. (2005). L1, a novel target of beta-catenin signaling, transforms cells and is expressed at the invasive front of colon cancers. J Cell Biol 168: 633-642.
22. Gomez E, Pritchard C, Herbert TP. (2002). cAMP-dependent protein kinase and Ca2+ influx through L-type voltage-gated calcium channels mediate Raf-independent activation of extracellular regulated kinase in response to glucagon-like peptide-1 in pancreatic beta-cells. J Biol Chem 277: 48146-48151.
23. Hanahan D. (1985). Heritable formation of pancreatic beta-cell tumours in transgenic mice expressing recombinant insulin/simian virus 40 oncogenes. Nature 315: 115-122.
24. Hashizume H, Baluk P, Morikawa S, McLean JW, Thurston G, Roberge S et al. (2000). Openings between defective endothelial cells explain tumor vessel leakiness. Am J Pathol 156: 1363-1380.
25. Herbert TP, Tee AR, Proud CG. (2002). The extracellular signal-regulated kinase pathway regulates the phosphorylation of 4E-BP1 at multiple sites. J Biol Chem 277: 11591-11596.
26. Herzig M, Novatchkova M, Christofori G. (1999). An unexpected role for p53 in augmenting SV40 large T antigen-mediated tumorigenesis. Biol Chem 380: 203-211.
27. Inoue M, Hager JH, Ferrara N, Gerber HP, Hanahan D. (2002). VEGF-A has a critical, nonredundant role in angiogenic switching and pancreatic beta cell carcinogenesis. Cancer Cell 1: 193-202.
28. Krones-Herzig A, Adamson E, Mercola D. (2003). Early growth response 1 protein, an upstream gatekeeper of the p53 tumor suppressor, controls replicative senescence. PNAS 100: 3233-3238.
29. Krones-Herzig A, Mittal S, Yule K, Liang H, English C, Urcis R et al. (2005). Early growth response 1 acts as a tumor suppressor in vivo and in vitro via regulation of p53. Cancer Res 65: 5133-5143.
30. Lee CG, Cho SJ, Kang MJ, Chapoval SP, Lee PJ, Noble PW et al. (2004). Early growth response gene 1-mediated apoptosis is essential for transforming growth factor beta1-induced pulmonary fibrosis. J Exp Med 200: 377-389.
31. Lim K-H, Counter CM. (2005). Reduction in the requirement of oncogenic Ras signaling to activation of PI3K/AKT pathway during tumor maintenance. Cancer Cell 8: 381-392.
32. Mikula M, Schreiber M, Husak Z, Kucerova L, Ruth J, Wieser R et al. (2001). Embryonic lethality and fetal liver apoptosis in mice lacking the c-raf- 1 gene. Embo J 20: 1952-1962.
33. Morrison TB, Weis JJ, Wittwer CT. (1998). Quantification of low-copy transcripts by continuous SYBR Green I monitoring during amplification. Biotechniques 24: 954-958, 960, 962.
34. Nozawa H, Chiu C, Hanahan D. (2006). Infiltrating neutrophils mediate the initial angiogenic switch in a mouse model of multistage carcinogenesis. Proc Natl Acad Sci USA 103: 12493-12498.
35. Pannu J, Nakerakanti S, Smith E, ten Dijke P, Trojanowska M. (2007). Transforming growth factor-beta receptor type I-dependent fibrogenic gene program is mediated via activation of Smad1 and ERK1/2 pathways. J Biol Chem 282: 10405-10413.
36. Perl AK, Dahl U, Wilgenbus P, Cremer H, Semb H, Christofori G. (1999). Reduced expression of neural cell adhesion molecule induces metastatic dissemination of pancreatic beta tumor cells. Nat Med 5: 286-291.
37. Rolli-Derkinderen M, Machavoine F, Baraban JM, Grolleau A, Beretta L, Dy M. (2003). ERK and p38 inhibit the expression of 4E-BP1 repressor of translation through induction of Egr-1. J Biol Chem 278: 18859-18867.
38. Roux PP, Ballif BA, Anjum R, Gygi SP, Blenis J. (2004). Tumor-promoting phorbol esters and activated Ras inactivate the tuberous sclerosis tumor suppressor complex via p90 ribosomal S6 kinase. Proc Natl Acad Sci USA 101: 13489-13494.
39. Solit DB, Garraway LA, Pratilas CA, Sawai A, Getz G, Basso A et al. (2006). BRAF mutation predicts sensitivity to MEK inhibition. Nature 439: 358-362.
40. Sugimoto H, Mundel TM, Kieran MW, Kalluri R. (2006). Identification of fibroblast heterogeneity in the tumor microenvironment. Cancer Biol Ther 5: 1640-1646.
41. Ueda T, Watanabe-Fukunaga R, Fukuyama H, Nagata S, Fukunaga R. (2004). Mnk2 and Mnk1 are essential for constitutive and inducible phosphorylation of eukaryotic initiation factor 4E but not for cell growth or development. Mol Cell Biol 24: 6539-6549.
42. Wang X, Proud CG, Jon L. (2007). Methods in Enzymology, Vol. 431 Academic Press: New York, pp 113-142.
43. Waskiewicz AJ, Flynn A, Proud CG, Cooper JA. (1997). Mitogen-activated protein kinases activate the serine/threonine kinases Mnk1 and Mnk2. Embo J 16: 1909-1920.
44. Wellbrock C, Karasarides M, Marais R. (2004). The RAF proteins take centre stage. Nat Rev Mol Cell Biol 5: 875-885.
45. Xian X, Hakansson J, Stahlberg A, Lindblom P, Betsholtz C, Gerhardt H et al. (2006). Pericytes limit tumor cell metastasis. J Clin Invest 116: 642-651.